Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Non-cash Items (2019 - 2025)

Maxcyte (MXCT) has disclosed Non-cash Items for 6 consecutive years, with $14.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-cash Items fell 30.57% to $14.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.4 million, a 30.57% decrease, with the full-year FY2024 number at $8.5 million, down 12.15% from a year prior.
  • Non-cash Items was $14.4 million for Q3 2025 at Maxcyte, down from $19.5 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $35.4 million in Q1 2022 to a low of $66547.0 in Q4 2021.
  • A 5-year average of $23.1 million and a median of $23.7 million in 2022 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: tumbled 99.9% in 2021, then surged 35701.76% in 2022.
  • Maxcyte's Non-cash Items stood at $66547.0 in 2021, then soared by 35701.76% to $23.8 million in 2022, then tumbled by 33.46% to $15.9 million in 2023, then tumbled by 46.59% to $8.5 million in 2024, then surged by 69.74% to $14.4 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Non-cash Items are $14.4 million (Q3 2025), $19.5 million (Q2 2025), and $22.2 million (Q1 2025).